

**REPORT TO THE TWENTY-SEVENTH HAWAII STATE LEGISLATURE
2013**

**IN ACCORDANCE WITH THE PROVISIONS OF
SECTION 346-59.9, HAWAII REVISED STATUTES
ON PSYCHOTROPIC MEDICATION**

**DEPARTMENT OF HUMAN SERVICES
MED-QUEST DIVISION
DECEMBER 2012**

**2012 ANNUAL REPORT ON PSYCHOTROPIC MEDICATION,
SECTION 346-59.9, HAWAII REVISED STATUTES.**

Act 205, Session Laws of Hawaii (SLH) 2010, amended section 346-59.9, Hawaii Revised Statutes (HRS), Psychotropic Medication. Section 346-59.9 (g), now requires the Department of Human Services to report on:

- (1) The number of brand-name and generic prescriptions written to which this section applies; and
- (2) The amount expended on brand-name prescriptions and the amount expended on generic prescriptions written each fiscal year to which this section applies.

The information is provided in the tables below.

All Programs Combined

| | | Total Number of Claims | | | | Total Expenditures | | | |
|-----------------------|--------------------|------------------------|-----|---------|------|--------------------|-----|-------------|-----|
| | | Brand | | Generic | | Brand | | Generic | |
| | | # | % | # | % | # | % | # | % |
| Antipsychotic | | | | | | | | | |
| | 7/1/2009-6/30/2010 | 41,898 | 77% | 12,280 | 23% | \$20,199,429 | 93% | \$1,462,866 | 7% |
| | 7/1/2010-6/30/2011 | 44,617 | 77% | 13,087 | 23% | \$25,242,305 | 95% | \$1,390,106 | 5% |
| | 7/1/2011-6/30/2012 | 37,117 | 60% | 24,673 | 40% | \$23,542,507 | 81% | \$5,385,560 | 19% |
| Antidepressant | | | | | | | | | |
| | 7/1/2009-6/30/2010 | 22,369 | 25% | 66,591 | 75% | \$3,404,656 | 60% | \$2,293,131 | 40% |
| | 7/1/2010-6/30/2011 | 18,682 | 19% | 79,565 | 81% | \$2,914,236 | 51% | \$2,829,749 | 49% |
| | 7/1/2011-6/30/2012 | 13,438 | 13% | 91,666 | 87% | \$2,482,097 | 50% | \$2,521,850 | 50% |
| Anti-anxiety | | | | | | | | | |
| | 7/1/2009-6/30/2010 | 293 | 1% | 52,684 | 99% | \$40,861 | 7% | \$585,830 | 93% |
| | 7/1/2010-6/30/2011 | 258 | 0% | 54,814 | 100% | \$39,669 | 6% | \$617,857 | 94% |
| | 7/1/2011-6/30/2012 | 153 | 0% | 59,334 | 100% | \$39,009 | 6% | \$621,207 | 94% |

Medicaid Fee-For-Service (FFS) Program Only

| | | Total Number of Claims | | | | Total Expenditures | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|--------------------|-----|----------|------|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | # | % | # | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 761 | 86% | 122 | 14% | \$252,587 | 96% | \$11,782 | 4% | 357 |
| | 7/1/10-6/30/11 | 456 | 77% | 134 | 23% | \$155,982 | 93% | \$12,265 | 7% | 248 |
| | 7/1/11-6/30/12 | 269 | 57% | 206 | 43% | \$118,338 | 80% | \$29,127 | 20% | 196 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 165 | 20% | 643 | 80% | \$18,826 | 50% | \$18,881 | 50% | 447 |
| | 7/1/10-6/30/11 | 90 | 13% | 621 | 87% | \$11,535 | 38% | \$18,665 | 62% | 372 |
| | 7/1/11-6/30/12 | 43 | 8% | 515 | 92% | \$6,531 | 34% | \$12,631 | 66% | 307 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 0 | 0% | 354 | 100% | \$0 | 0% | \$2,941 | 100% | 239 |
| | 7/1/10-6/30/11 | 0 | 0% | 265 | 100% | \$0 | 0% | \$3,155 | 100% | 204 |
| | 7/1/11-6/30/12 | 0 | 0% | 237 | 100% | \$0 | 0% | \$3,092 | 100% | 173 |

* Note: Updates have been included due to correction in claims adjudication on the past reports.

QUEST Program
AlohaCare*

| | | Total Number of Claims | | | | Total Expenditures | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|--------------------|-----|-----------|------|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | # | % | # | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 5,887 | 85% | 1,022 | 15% | \$2,182,797 | 94% | \$141,089 | 6% | 1,259 |
| | 7/1/10-6/30/11 | 6,513 | 81% | 1,497 | 19% | \$2,898,060 | 94% | \$187,637 | 6% | 1,426 |
| | 7/1/11-6/30/12 | 5,011 | 64% | 2,816 | 36% | \$2,583,783 | 83% | \$511,103 | 17% | 1,400 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 4,380 | 26% | 12,376 | 74% | \$602,689 | 59% | \$423,742 | 41% | 3,355 |
| | 7/1/10-6/30/11 | 3,601 | 20% | 14,663 | 80% | \$514,498 | 46% | \$608,333 | 54% | 3,705 |
| | 7/1/11-6/30/12 | 2,313 | 12% | 16,653 | 88% | \$378,474 | 38% | \$621,115 | 62% | 3,654 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 15 | 0% | 8,206 | 100% | \$2,505 | 3% | \$79,318 | 97% | 1,786 |
| | 7/1/10-6/30/11 | 18 | 0% | 8,111 | 100% | \$1,951 | 2% | \$80,947 | 98% | 1,894 |
| | 7/1/11-6/30/12 | 2 | 0% | 8,340 | 100% | \$247 | 0% | \$93,660 | 100% | 1,835 |

* Note: Updates have been included due to correction in claims adjudication on the past reports.

QUEST Program
HMSA QUEST

| | | Total Number of Claims | | | | Total Expenditures | | | | Total No. Unique Utilizers |
|----------------|----------------|------------------------|-----|---------|------|--------------------|-----|-----------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | # | % | # | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 11,615 | 83% | 2,430 | 17% | \$4,319,335 | 96% | \$160,146 | 4% | 2,127* |
| | 7/1/10-6/30/11 | 11,050 | 85% | 1,950 | 15% | \$4,767,415 | 98% | \$87,976 | 2% | 809 |
| | 7/1/11-6/30/12 | 9,978 | 66% | 5,175 | 34% | \$4,959,122 | 88% | \$657,413 | 12% | 890 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 8,864 | 27% | 24,262 | 73% | \$1,185,654 | 58% | \$875,185 | 42% | 5,565* |
| | 7/1/10-6/30/11 | 7,248 | 19% | 30,028 | 81% | \$1,014,205 | 52% | \$934,533 | 48% | 2,343 |
| | 7/1/11-6/30/12 | 5,110 | 13% | 34,478 | 87% | \$895,929 | 54% | \$772,525 | 46% | 2,482 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 18 | 0% | 11,536 | 100% | \$5,910 | 4% | \$137,248 | 96% | 2,360* |
| | 7/1/10-6/30/11 | 83 | 1% | 11,429 | 99% | \$8,346 | 7% | \$113,308 | 93% | 849 |
| | 7/1/11-6/30/12 | 17 | 0% | 13,246 | 100% | \$4,540 | 4% | \$115,424 | 96% | 845 |

* The change of a pharmacy claims processor during this period results in some inconsistencies in data sets.

QUEST Program
Kaiser

| | | Total Number of Claims | | | | Total Expenditures | | | | Total No. Unique Utilizers |
|----------------|----------------|------------------------|-----|---------|------|--------------------|-----|----------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | # | % | # | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 714 | 53% | 628 | 47% | \$210,251 | 98% | \$3,932 | 2% | 289 |
| | 7/1/10-6/30/11 | 853 | 54% | 730 | 46% | \$301,307 | 98% | \$6,176 | 2% | 360 |
| | 7/1/11-6/30/12 | 625 | 38% | 1,023 | 62% | \$258,603 | 89% | \$32,444 | 11% | 372 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 497 | 8% | 5,857 | 92% | \$75,263 | 66% | \$38,422 | 34% | 1,181 |
| | 7/1/10-6/30/11 | 463 | 6% | 6,968 | 94% | \$80,249 | 66% | \$41,292 | 34% | 1,378 |
| | 7/1/11-6/30/12 | 485 | 5% | 8,444 | 95% | \$107,488 | 66% | \$55,350 | 34% | 1,589 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 1 | 0% | 2,469 | 100% | \$147 | 3% | \$4,851 | 97% | 648 |
| | 7/1/10-6/30/11 | 1 | 0% | 2,789 | 100% | \$661 | 11% | \$5,101 | 89% | 777 |
| | 7/1/11-6/30/12 | 15 | 1% | 2,972 | 99% | \$5,503 | 53% | \$4,915 | 47% | 867 |

QUEST Expanded Access (QExA) Program
Ohana Health Plan

| | | Total Number of Claims | | | | Total Expenditures | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|------|--------------------|-----|-------------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | # | % | # | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 15,653 | 76% | 5,068 | 24% | \$7,510,115 | 92% | \$645,522 | 8% | 1,944 |
| | 7/1/10-6/30/11 | 18,771 | 76% | 6,008 | 24% | \$10,069,923 | 93% | \$701,013 | 7% | 2,164 |
| | 7/1/11-6/30/12 | 15,357 | 58% | 11,280 | 42% | \$9,537,668 | 75% | \$3,122,545 | 25% | 2,127 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 5,462 | 26% | 15,688 | 74% | \$786,111 | 60% | \$519,290 | 40% | 2,559 |
| | 7/1/10-6/30/11 | 5,335 | 22% | 19,287 | 78% | \$754,409 | 49% | \$800,750 | 51% | 2,846 |
| | 7/1/11-6/30/12 | 4,310 | 16% | 22,277 | 84% | \$736,653 | 49% | \$774,715 | 51% | 2,856 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 76 | 0% | 18,057 | 100% | \$21,672 | 11% | \$171,815 | 89% | 2,931 |
| | 7/1/10-6/30/11 | 49 | 0% | 19,805 | 100% | \$17,288 | 8% | \$191,471 | 92% | 3,032 |
| | 7/1/11-6/30/12 | 48 | 0% | 21,810 | 100% | \$18,985 | 8% | \$207,492 | 92% | 3,123 |

QUEST Expanded Access (QExA) Program
United HealthCare Community Plan (formerly known as Evercare)

| | | Total Number of Claims | | | | Total Expenditures | | | | Total No. Unique Utilizers |
|-----------------------|----------------|------------------------|-----|---------|-----|--------------------|-----|-------------|-----|----------------------------|
| | | Brand | | Generic | | Brand | | Generic | | |
| | | # | % | # | % | # | % | # | % | |
| Antipsychotic | | | | | | | | | | |
| | 7/1/09-6/30/10 | 7,268 | 71% | 3,010 | 29% | \$5,724,344 | 92% | \$500,395 | 8% | 2,045 |
| | 7/1/10-6/30/11 | 6,974 | 72% | 2,768 | 28% | \$7,049,618 | 95% | \$395,039 | 5% | 1,638 |
| | 7/1/11-6/30/12 | 5,877 | 58% | 4,173 | 42% | \$6,084,993 | 85% | \$1,032,928 | 15% | 1,506 |
| Antidepressant | | | | | | | | | | |
| | 7/1/09-6/30/10 | 3,001 | 28% | 7,765 | 72% | \$736,113 | 64% | \$417,611 | 36% | 2,697 |
| | 7/1/10-6/30/11 | 1,945 | 20% | 7,998 | 80% | \$539,340 | 56% | \$426,176 | 44% | 2,108 |
| | 7/1/11-6/30/12 | 1,177 | 11% | 9,299 | 89% | \$357,022 | 56% | \$285,514 | 44% | 2,004 |
| Anti-anxiety | | | | | | | | | | |
| | 7/1/09-6/30/10 | 183 | 1% | 12,062 | 99% | \$10,627 | 5% | \$189,657 | 95% | 2,640 |
| | 7/1/10-6/30/11 | 107 | 1% | 12,415 | 99% | \$11,423 | 5% | \$223,875 | 95% | 2,889 |
| | 7/1/11-6/30/12 | 71 | 1% | 12,729 | 99% | \$9,734 | 5% | \$196,624 | 95% | 2,839 |

Discussion

Act 205, SLH 2010, was effective July 1, 2011 and implemented by the different plans during different quarters in State Fiscal Year (SFY) 2010-2011. SFY 2011-2012 is a full year for implementation of Act 205 by all the plans. Data for State Fiscal Year 2009-2010, prior to the implementation of Act 205, SLH 2010, is represented for comparison purposes.

Different approaches and combinations were initiated by the different plans, such as the following: Preferred Drug Lists/Formulary Coverage, Prospective DUR edits, Point-Of-Sale messaging, Step Therapy, Prior Authorization, Provider Education and Call Center intervention.

In SFY 2009-2010, the All Programs Combined antianxiety generic prescribing rate was 99% and increased to 100% by SFY 2011-2012. Act 205 had minimal impact on antianxiety prescribing because the generic rate was already extremely high. However, for antidepressants, the generic prescribing rate increased from 75% in SFY 2009-2010 to 87% in SFY 2011-2012. During this period, the number of prescriptions for an antidepressant increased by 18%; however, the expenditures on antidepressants decreased by 12% due to the shift from brand to generic.

Section 346-59.9, Hawaii Revised Statutes, requires unrestricted antipsychotic prescribing. However, the generic prescribing rate increased from 23% in SFY 2009-2010 to 40% in SFY 2011-2012. This shift was likely due to three (3) major brand antipsychotics becoming available in generic forms during SFY 2011-2012: Olanzapine for Zyprexa® as of November 2011; Quetiapine for Seroquel® as of March 2012 and Ziprasidone for Geodon® as of March 2012. In addition, to help ensure safety, the Med-QUEST Division (MQD) issued guidance to health plans regarding use of antipsychotics for Food and Drug Administration (FDA) approved diagnoses, FDA approved age criteria, Quantity Limits (FDA approved and dose optimization), Post-payment Reviews and Case Management. Nevertheless, the 60% of antipsychotic prescriptions that were filled with brand medications comprised 80% of the expenditures on antipsychotic medications at a cost of more than \$23 million.

By State law, the MQD cannot limit or restrict access to antipsychotic medications despite national efforts to reduce over-prescribing among children, particularly foster care children. Changes to Act 205 could give MQD the authority to proactively work to reduce over-prescribing among children such as through prior authorization, which has become a national best practice.